Sandoz receives FDA approval for Zarxio
Sandoz, a Novartis company, is the first in the US to receive the approval through the new FDA biosimilars pathway established under the Biologics Price Competition and Innovation
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
The grant has been given to clinically advance Irofulven for the treatment of metastatic castration resistant prostrate cancer (mCRPC) by utilising a highly predictive biomarker for the drug
Although the results from both placebo (36.5 mm improvement from baseline, p < 0.0001) and Tradipitant (40.5mm improvement from baseline, p < 0.0001) displayed significant and clinically meaningful